Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows

Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large Phase 3 trial. The study, “Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial,” was presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. At the same time, the findings, “Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer,” were also published in the New England Journal of Medicine.  Xtandi, marketed by Pfizer and Astellas Pharma, is an oral androgen receptor approved to treat prostate cancer that no longer responds to medical or surgical treatment intended to lower testosterone. To address whether Xtandi also works in prostate cancers that are responding to testosterone-lowering treatments, researchers designed the multi-center, global and investigator-initiated ENZAMET trial (NCT02446405). The study is being led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, partially funded by Astellas Pharma, and supported by The University of Sydney, the Canadian Cancer Trials Group, Dana-Farber Cancer Institute, and Cancer Trials Ireland. It included 1,125 patients, followed over a median 34 months, who received Xtandi or standard androgen receptor inhibitors in addition to testosterone suppression, with or without docetaxel. Early results showed that 80% of the men treated with testosterone suppression and Xtandi were alive after
Subscribe or to access all post and page content.